

2020 Information

Date of announcement	Date of announcement	Statement
2020/2/4	16:06:51	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2020/02/05</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:20F., No. 2, Sec. 1, Chongqing S. Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: https://webpro.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified: NA</p>
2020/3/13	18:36:44	<p>Convention of 2020 general shareholders' meeting.</p> <p>1.Date of the board of directors resolution:2020/03/13</p> <p>2.Date for convening the shareholders' meeting:2020/06/19</p> <p>3.Location for convening the shareholders' meeting: No.55, Changrong Rd., Luzhu Dist., Taoyuan City, Taiwan (Freedom design hotel)</p> <p>4.Cause or subjects for convening the meeting</p> <p>(1) Report Items:</p> <p style="padding-left: 20px;">(1) Report on the compensation for employees and directors of 2019</p> <p style="padding-left: 20px;">(2) Report on operating results of 2019</p> <p style="padding-left: 20px;">(3) Report by Audit Committee on auditing of 2019 financial statements</p> <p style="padding-left: 20px;">(4) Report on donation to related parties</p> <p style="padding-left: 20px;">(5) Amendment to Rules of Procedure for Board of Directors Meetings</p> <p style="padding-left: 20px;">(6) Amendment to Ethical Corporate Management Best Practice Principles</p> <p style="padding-left: 20px;">(7) Amendment to Corporate Social Responsibility Best Practice Principles</p> <p>5.Cause or subjects for convening the meeting</p> <p>(2) Matters for Ratification:</p> <p style="padding-left: 20px;">(1) Recognition of 2019 operation report and financial statements</p> <p style="padding-left: 20px;">(2) Distribution of retained earnings</p> <p>6.Cause or subjects for convening the meeting</p> <p>(3) Matters for Discussion:</p> <p style="padding-left: 20px;">(1) Amendment to Rules of Procedure for Shareholders Meetings</p> <p style="padding-left: 20px;">(2) Amendment to Regulation Governing Loaning of Funds</p> <p style="padding-left: 20px;">(3) Amendment to Regulation Making of Endorsements/Guarantees</p> <p>7.Cause or subjects for convening the meeting</p> <p>(4) Elections: N/A</p>

		<p>8.Cause or subjects for convening the meeting (5) Other Proposals: N/A</p> <p>9.Cause or subjects for convening the meeting (6) Extemporany Motions: N/A</p> <p>10.Book closure starting date:2020/04/21</p> <p>11.Book closure ending date:2020/06/19</p> <p>12.Any other matters that need to be specified: N/A</p>
2020/3/13	18:37:06	<p>Donation to related party.</p> <p>1.Date of occurrence of the event:2020/03/13</p> <p>2.The reason for the donation: Support Criminal study</p> <p>3.The total amount of the donation: NTD300,000</p> <p>4.Counterparty to the donation: Criminal Investigation Foundation of R.O.C.</p> <p>5.Relationship to the Company: Related Party</p> <p>6.Name and resume of the independent director that expressed objection or reservation: NA</p> <p>7.Contents of the objection or reservation: NA</p> <p>8.Any other matters that need to be specified: NA</p>
2020/3/13	18:37:29	<p>Board of Directors approved the compensation for employees and directors of 2019</p> <p>1.Date of occurrence of the event:2020/03/13</p> <p>2.Company name: SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios: NA</p> <p>5.Cause of occurrence: NA</p> <p>6.Countermeasures:NA</p> <p>7.Any other matters that need to be specified:</p> <p>(1) Employees' compensation was NT\$69,459,131</p> <p>(2) Directors' compensation was NT\$9,301,245</p> <p>(3) The above compensations will be distributed in cash.</p> <p>(4) The total amount approved is not different from the expense recognized in 2019 financial statements.</p>
2020/3/13	18:47:48	<p>The Board proposed earnings distribution.</p> <p>1.Date of the board of directors resolution :2020/03/13</p> <p>2.Appropriations of earnings in cash dividends to shareholders (NT\$ per share):5.8</p> <p>3.Cash distributed from legal reserve and capital surplus to shareholders (NT\$ per share):0</p> <p>4.Total amount of cash distributed to shareholders (NT\$):461,014,798</p> <p>5.Appropriations of earnings in stock dividends to shareholders (NT\$ per share):0</p>

		<p>6. Stock distributed from legal reserve and capital surplus to shareholders (NT\$ per share): 0</p> <p>7. Total amount of stock distributed to shareholders (shares): 0</p> <p>8. Any other matters that need to be specified: NA</p>																														
2020/3/30	17:09:17	<p>Announce the financial and business information, because of the announcement of attention to trading information.</p> <p>1. Date of occurrence of the event: 2020/03/30</p> <p>2. Cause of occurrence: According to TWSE's instruction</p> <p>3. Financial and business information:</p> <p style="text-align: right;">in thousands of NTD</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th style="text-align: center;">latest month (2020/02)</th> <th style="text-align: center;">Compared with the same period of last year(%)</th> <th style="text-align: center;">latest quarter (2019.Q4)</th> <th style="text-align: center;">Compared with the same period of last year(%)</th> <th style="text-align: center;">2019/01 to 2019/12</th> </tr> </thead> <tbody> <tr> <td>Revenues</td> <td style="text-align: right;">237,366</td> <td style="text-align: right;">8.54%</td> <td style="text-align: right;">519,959</td> <td style="text-align: right;">11.96%</td> <td style="text-align: right;">2,355,747</td> </tr> <tr> <td>Profit before tax</td> <td style="text-align: right;">83,247</td> <td style="text-align: right;">-12%</td> <td style="text-align: right;">106,108</td> <td style="text-align: right;">-19.74%</td> <td style="text-align: right;">711,160</td> </tr> <tr> <td>Profit</td> <td style="text-align: right;">66,598</td> <td style="text-align: right;">-12%</td> <td style="text-align: right;">89,498</td> <td style="text-align: right;">-18.83%</td> <td style="text-align: right;">571,101</td> </tr> <tr> <td>EPS</td> <td style="text-align: right;">0.84</td> <td style="text-align: right;">-12%</td> <td style="text-align: right;">1.13</td> <td style="text-align: right;">-18.71%</td> <td style="text-align: right;">7.19</td> </tr> </tbody> </table> <p>PS. Financial figures above have not been unaudited by CPA firm.</p> <p>4. Any matters regarding to "Taiwan stock exchange corporation procedure for verification and disclosure of material information of companies with listed securities" article 4 that need to be specified: NA</p> <p>5. Any matters regarding to "Taiwan stock exchange corporation procedure for verification and disclosure of material information of companies with listed securities" article 11 that need to be specified: NA</p> <p>6. Any other matters that need to be specified: NA</p>		latest month (2020/02)	Compared with the same period of last year(%)	latest quarter (2019.Q4)	Compared with the same period of last year(%)	2019/01 to 2019/12	Revenues	237,366	8.54%	519,959	11.96%	2,355,747	Profit before tax	83,247	-12%	106,108	-19.74%	711,160	Profit	66,598	-12%	89,498	-18.83%	571,101	EPS	0.84	-12%	1.13	-18.71%	7.19
	latest month (2020/02)	Compared with the same period of last year(%)	latest quarter (2019.Q4)	Compared with the same period of last year(%)	2019/01 to 2019/12																											
Revenues	237,366	8.54%	519,959	11.96%	2,355,747																											
Profit before tax	83,247	-12%	106,108	-19.74%	711,160																											
Profit	66,598	-12%	89,498	-18.83%	571,101																											
EPS	0.84	-12%	1.13	-18.71%	7.19																											
2020/4/10	16:24:57	<p>SCI's board of directors has approved the signing of a shareholder agreement.</p> <p>1. Date of occurrence of the event: 2020/04/10</p> <p>2. Company name: SCI Pharmtech, Inc.</p> <p>3. Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4. Reciprocal shareholding ratios: NA</p> <p>5. Cause of occurrence: (1) SCI and Veolia Environment (Veolia) will form a joint venture company</p>																														

		<p>(the Company), holding 40% and 60% of outstanding shares, respectively. The Company will engage in circular economy by purifying and utilizing used solvents.</p> <p>(2) Both parties will provide the Company with funding, endorsement and guarantee and own director seats in proportion to their shareholdings.</p> <p>(3) The Veolia will be in charge of the Company's daily operation.</p> <p>(4) The Company will rent the land owned by Yushan Pharmaceuticals Inc., SCI's subsidiary, for its premises.</p> <p>6.Countermeasures:NA</p> <p>7.Any other matters that need to be specified: NA</p>
2020/4/10	16:25:17	<p>To donate Hydroxychloroquine Sulfate.</p> <p>1.Date of occurrence of the event:2020/04/10</p> <p>2.Company name: SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4.Reciprocal shareholding ratios: NA</p> <p>5.Cause of occurrence: SCI's board approved to donate one metric ton of Hydroxychloroquine Sulfate to CDC in the fight against COVID-19.</p> <p>6.Countermeasures:NA</p> <p>7.Any other matters that need to be specified: NA</p>
2020/4/14	16:42:39	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2020/04/15</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference: Web conference</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: https://webpro.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw</p>

2020/4/30	15:32:36	<p>To clarify online news published by money.udn.com</p> <p>1.Date of occurrence of the event:2020/04/30</p> <p>2.Company name: SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4.Reciprocal shareholding ratios: Not applicable</p> <p>5.Name of the reporting media: money.udn.com</p> <p>6.Content of the report: Academia Sinica synthesized Remdesivir within two weeks. In the future, API and generic drug companies are likely to join hands, which include</p>
2020/5/21	14:13:26	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2020/05/22</p> <p>2.Time of the investor conference:14:00</p> <p>3.Location of the investor conference: Web conference</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: https://webpro.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw</p>
2020/6/19	15:24:09	<p>Notice of the resolutions of 2020 general shareholders' meeting.</p> <p>1.Date of the shareholders meeting:2020/06/19</p> <p>2.Important resolutions (1)Profit distribution/ deficit compensation: Approved the distribution of retained earnings. 45,326,099 shares represented by shareholders present in person or by proxy. (including 40,429,833 shares casted electronically) approval votes : 43,445,709 votes - 95.85% of the total represented at the time of voting. disapproval votes : 84,768 votes - 0.18% of the total represented at the time of voting.</p>

2020/6/24	17:15:05	<p>Notice of the record date for common share dividend.</p> <p>1.Date of the resolution by the board of directors or shareholders meeting or decision by the Company:2020/06/24</p> <p>2.Type of ex-rights or ex-dividend (please enter: "Ex-rights", "Ex-dividend", or "Ex-rights and dividend"):Ex-dividend</p> <p>3.Type and monetary amount of dividend distribution: Cash dividends of NT\$461,014,798</p> <p>4.Ex-rights (ex-dividend) trading date:2020/07/13</p> <p>5.Last date before book closure:2020/07/14</p>
2020/8/19	15:25:09	<p>Invited to brief recent operating results.</p> <p>1.Date of institutional investor conference:2020/08/20</p> <p>2.Time of institutional investor conference:14:30</p> <p>3.Location of institutional investor conference: 7F., No. 236, Sec. 4, Xinyi Rd., Taipei City</p> <p>4.Outline of institutional investor conference: Brief recent operating results</p> <p>5.Any other matters that need to be specified: NA</p>
2020/11/06	17:37:34	<p>Figures of the third-quarter consolidated financial statements reported to Board of Directors.</p> <p>1.Date of the financial reports submitted to the board of directors or approved by the board of directors:2020/11/06</p> <p>2.Date of the financial reports approved by the audit committee: N/A</p> <p>3.Year/Quarter of financial reports:2020/Q3</p> <p>4.Accumulated operating revenue in the reporting period (thousand NTD):2,191,085</p> <p>5. Accumulated gross profit (loss) from operations in the reporting period (thousand</p>
2020/11/06	17:46:31	<p>Donation to related party.</p> <p>1.Date of occurrence of the event:2020/11/06</p> <p>2.Reason for the donation: Support Criminal Study</p> <p>3.Total amount of the donation: NT\$600,000</p> <p>4.Counterparty to the donation: Criminal Investigation Foundation of R.O.C.</p> <p>5.Relationship with the Company: Related Party</p> <p>6.Name and resume of independent director(s) that expressed an objection or</p>